Novartis Licenses Caliper's In Vivo Imaging IP Suite | GenomeWeb
NEW YORK (GenomeWeb News) — Novartis has licensed Caliper Life Sciences’ intellectual property covering non-invasive optical imaging methods, Caliper said today.
 
Under the multi-year agreement, the drug maker will use Caliper’s Optical Imaging patent suite, which includes imaging systems, reagents, related applications, and methods and services, Caliper said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.